Fourteen-Day Evolution of COVID-19 Symptoms during the Third Wave in Nonvaccinated Subjects and Effects of Hesperidin Therapy: A Randomized, Double-Blinded, Placebo-Controlled Study

Table 2

Proportion of patients with group A COVID-19 symptoms, intent-to-treat population.

	Placebo	Hesperidin	All	OR (95% CI)^a	value^a
Day 1	N = 107	N = 104	N = 211
No	12 (11.2%)	12 (11.5%)	24 (11.4%)
Yes^b	95 (88.8%)	92 (88.5%)	187 (88.6%)	0.97 (0.41; 2.28)	0.9413
Day 3	N = 103	N = 102	N = 205
No	13 (12.6%)	9 (8.8%)	22 (10.7%)
Yes^b	90 (87.4%)	93 (91.2%)	183 (89.3%)	1.49 (0.60; 3.69)	0.3849
Day 7	N = 101	N = 91	N = 192
No	25 (24.8%)	17 (18.7%)	42 (21.9%)
Yes^b	76 (75.2%)	74 (81.3%)	150 (78.1%)	1.43 (0.71; 2.88)	0.3139
Day 10	N = 99	N = 90	N = 189
No	39 (39.4%)	32 (35.6%)	71 (37.6%)
Yes^b	60 (60.6%)	58 (64.4%)	118 (62.4%)	1.18 (0.65; 2.14)	0.5886
Day 14	N = 94	N = 79	N = 173
No	39 (41.5%)	40 (50.6%)	79 (45.7%)
Yes^b	55 (58.5%)	39 (49.4%)	94 (54.3%)	0.69 (0.38; 1.27)	0.2328

^aComparison between the placebo group and hesperidin group. Significant when . ^bSubject has at least one of the group A COVID-19 symptoms: fever, cough, shortness of breath, or anosmia. N represents the number of subjects who completed the daily symptom diary.